NDAORALTABLETPriority Review
Approved
Mar 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
13
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BLUJEPA (gepotidacin) is a novel oral small-molecule antibiotic approved by the FDA on March 25, 2025. The specific mechanism of action and approved indications are not yet publicly detailed in available data, but it represents a new chemical entity in GSK's infectious disease portfolio. This is an oral tablet formulation designed for broad clinical utility.
Growth16.4 years to LOE
Early-stage growth product with significant runway; commercial infrastructure and team expansion likely as market adoption accelerates.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (13)
A Study to Evaluate Gepotidacin Exposure in Breast Milk of Healthy Lactating Women
Started Jul 2026
8 enrolled
Urinary Tract Infections
A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)
Started Oct 2024
97 enrolled
Urinary Tract Infections
A Study to Investigate the Efficacy and Safety With Gepotidacin in Japanese Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis)
Started Jan 2023
380 enrolled
Urinary Tract Infections
A Study to Evaluate Pharmacokinetic, Safety, Tolerability and Relative Bioavailability of Gepotidacin in Healthy Adult Male and Female Participants
Started Mar 2022
24 enrolled
Healthy Volunteers
Drug-drug Interaction Study of Gepotidacin
Started Aug 2020
64 enrolled
Infections, Bacterial
Worked on BLUJEPA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.